Zinbryta Global Withdrawal Driven In Part By Difficulty Of Safety Assessment

 
• By Nielsen Hobbs

EMA safety investigation pushes decision as AbbVie, Biogen acknowledge 'characterizing the evolving benefit/risk profile … will not be possible going forward given the limited number of patients being treated.'

Vintage looking Withdrawn stamp on a book page

More from Drug Safety

More from Pink Sheet